|
|
Volumn 378, Issue 6, 2018, Pages 497-499
|
|
Redefining hypertension - Assessing the new blood-pressure guidelines
a,b b |
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOTENSIN ANTAGONIST;
ATENOLOL;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
CALCIUM ANTAGONIST;
DILTIAZEM;
DIURETIC AGENT;
RENIN INHIBITOR;
THIAZIDE DIURETIC AGENT;
ANTIHYPERTENSIVE AGENT;
ADVERSE OUTCOME;
BLOOD PRESSURE MONITORING;
BLOOD PRESSURE REGULATION;
BLOOD VESSEL COMPLIANCE;
CARDIOVASCULAR RISK;
CLINICAL OUTCOME;
DIABETES MELLITUS;
DIAGNOSTIC ACCURACY;
DIAGNOSTIC ERROR;
DIASTOLIC BLOOD PRESSURE;
HIGH RISK PATIENT;
HUMAN;
HYPERTENSION;
ISCHEMIC HEART DISEASE;
KIDNEY DISEASE;
LIFESTYLE MODIFICATION;
MEDICAL PRACTICE;
MEDICAL SOCIETY;
METABOLIC SYNDROME X;
PATIENT CARE;
PERSONALIZED MEDICINE;
PRACTICE GUIDELINE;
PREHYPERTENSION;
PRIORITY JOURNAL;
REVIEW;
RISK ASSESSMENT;
SYSTOLIC BLOOD PRESSURE;
ADULT;
AGED;
BLOOD PRESSURE MEASUREMENT;
CLASSIFICATION;
PROCEDURES;
RISK;
STANDARDS;
UNITED STATES;
ADULT;
AGED;
ANTIHYPERTENSIVE AGENTS;
BLOOD PRESSURE DETERMINATION;
HUMANS;
HYPERTENSION;
PRACTICE GUIDELINES AS TOPIC;
RISK;
SOCIETIES, MEDICAL;
UNITED STATES;
|
|
EID: 85042102875
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMp1716193 Document Type: Review |
|
Times cited : (93)
|
|
References (5)
|
